I'm excited to see possible parallel applications of this therapy for other hearing-loss related gene mutations such as GJB2.
From what I can tell from a press release from Regeneron themselves, they're also working on GJB2 and STRC therapies.
From what I can tell from a press release from Regeneron themselves, they're also working on GJB2 and STRC therapies.